Dinutuximab fails to meet its primary efficacy endpoint in phase II/III DISTINC trial in small cell lung cancer

Trial (n=471) of this GD2-binding monoclonal antibody combined with irinotecan vs irinotecan or topotecan alone in relapsed/refractory disease failed to demonstate an extension in overall survival with the combination. There were 312 deaths in the combination and irinotecan arms.

Biospace Inc.